Cost-effectiveness of telehealth for patients with raised cardiovascular disease risk: evidence from the Healthlines randomised controlled trial

Abstract

ObjectivesTo investigate the cost-effectiveness of a telehealth intervention for primary care patients with raised cardiovascular disease (CVD) risk.DesignA prospective within-trial patient-level economic evaluation conducted alongside a randomised controlled trial.SettingPatients recruited through primary care, and intervention delivered via telehealth service.ParticipantsAdults with a 10-year CVD risk ≥20%, as measured by the QRISK2 algorithm, with at least 1 modifiable risk factor.InterventionA series of up to 13 scripted, theory-led telehealth encounters with healthcare advisors, who supported participants to make behaviour change, use online resources, optimise medication and improve adherence. Participants in the control arm received usual care.Primary and secondary outcome measuresCost-effectiveness measured by net monetary benefit at the end of 12 months of follow-up, calculated from incremental cost and incremental quality-adjusted life years (QALYs). Productivity impacts, participant out-of-pocket expenditure and the clinical outcome were presented in a cost-consequences framework.Results641 participants were randomised—325 to receive the telehealth intervention in addition to usual care and 316 to receive only usual care. 18% of participants had missing data on either costs, utilities or both. Multiple imputation was used for the base case results. The intervention was associated with incremental mean per-patient National Health Service (NHS) costs of £138 (95% CI 66 to 211) and an incremental QALY gain of 0.012 (95% CI −0.001 to 0.026). The incremental cost-effectiveness ratio was £10 859. Net monetary benefit at a cost-effectiveness threshold of £20 000 per QALY was £116 (95% CI −58 to 291), and the probability that the intervention was cost-effective at this threshold value was 0.77. Similar results were obtained from a complete case analysis.ConclusionsThere is evidence to suggest that the Healthlines telehealth intervention was likely to be cost-effective at a threshold of £20 000 per QALY.Trial registration numberISRCTN27508731; Results. Prospectively registered 05 July 2012.

The impact of a remote monitoring system of healthcare resource consumption in patients on automated peritoneal dialysis (APD): A simulation study

“…RM is cost-effective for managing chronic obstructive pulmonary disease and congestive heart failure, with emerging positive economic data in diabetes care, management of elevated cardiovascular risk, and perhaps even depression [ 23 , 24 , 25 , 26 , 27 , 28 , 29 ]. Cost-savings in these scenarios are driven by improved efficiencies in care and reduced complications.…”

Remote Patient Management for Home Dialysis Patients

“…Although studies in other disease states have shown cost-effectiveness of telehealth interventions, studies evaluating the impact of RPM in the dialysis population are needed to justify its widespread use. 43 , 44 …”

Cost-effectiveness modelling of telehealth for patients with raised cardiovascular disease risk: evidence from a cohort simulation conducted alongside the Healthlines randomised controlled trial

“…The methods used for multiple imputation are described in further detail in the companion 12-month economic evaluation paper. 12 …”

“…The long-term cost-effectiveness analysis complements the analysis of cost-effectiveness of the intervention at 12 months postrandomisation published in a companion paper. 12 …”